ID: ALA4205901

Max Phase: Preclinical

Molecular Formula: C17H16ClF3N4O3S2

Molecular Weight: 444.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1nnc2sc(C(=O)NCc3ccc(S(=O)(=O)C(F)(F)F)cc3)c(N)c2c1C.Cl

Standard InChI:  InChI=1S/C17H15F3N4O3S2.ClH/c1-8-9(2)23-24-16-12(8)13(21)14(28-16)15(25)22-7-10-3-5-11(6-4-10)29(26,27)17(18,19)20;/h3-6H,7,21H2,1-2H3,(H,22,25);1H

Standard InChI Key:  FLLKGYASPVAHLS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 444.46

Molecular Weight (Monoisotopic): 444.0538

AlogP: 3.11

#Rotatable Bonds: 4

Polar Surface Area: 115.04

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.08

CX LogP: 3.37

CX LogD: 3.37

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.64

Np Likeness Score: -1.82

References

1. Tarr JC, Wood MR, Noetzel MJ, Melancon BJ, Lamsal A, Luscombe VB, Rodriguez AL, Byers FW, Chang S, Cho HP, Engers DW, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW..  (2017)  Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides.,  27  (23): [PMID:29089231] [10.1016/j.bmcl.2017.10.053]

Source

Source(1):

• Scientific Literature